Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;19(1):134-40.
doi: 10.1111/j.1365-2516.2012.02905.x. Epub 2012 Jul 5.

Liver transplant outcomes in HIV+ haemophilic men

M V Ragni  1 , M E Devera, M E Roland, M Wong, V Stosor, K E Sherman, D Hardy, E Blumberg, J Fung, B Barin, D Stablein, P G Stock
Affiliations

Liver transplant outcomes in HIV+ haemophilic men

M V Ragni et al. Haemophilia. 2013 Jan.

Abstract

Hepatitis C virus infection is the major cause of end-stage liver disease and the major indication for transplantation (OLTX), including among HIV-HCV co-infected individuals. The age of HCV acquisition differs between haemophilic and non-haemophilic candidates, which may affect liver disease outcomes. The purpose of the study was to compare rates of pre- and post-OLTX mortality between co-infected haemophilic and non-haemophilic subjects without hepatocellular cancer participating in the Solid Organ Transplantation in HIV Study (HIV-TR). Clinical variables included age, gender, race, liver disease aetiology, BMI, antiretroviral therapy, MELD score, CD4 + cell count, HIV RNA PCR and HCV RNA PCR. Time to transplant, rejection and death were determined. Of 104 HIV-HCV positive subjects enrolled, 34 (32.7%) underwent liver transplantation, including 7 of 15 (46.7%) haemophilic and 27 of 89 (30.3%) non-haemophilic candidates. Although haemophilic subjects were younger, median 41 vs. 47 years, P = 0.01, they were more likely than non-haemophilic subjects to die pre-OLTX, 5 (33.3%) vs. 13 (14.6%), P = 0.03, and reached MELD = 25 marginally faster, 0.01 vs. 0.7 years, P = 0.06. The groups did not differ in baseline BMI, CD4, detectable HIV RNA, detectable HCV RNA, time to post-OLTX death (P = 0.64), graft loss (P = 0.80), or treated rejection (P = 0.77). The rate of rejection was 14% vs. 36% at 1-year and 36% vs. 43% at 3-year, haemophilic vs. non-haemophilic subjects, respectively, and post-OLTX survival, 71% vs. 66% at 1-year and 38% vs. 53% at 3-year. Despite similar transplant outcomes, pretransplant mortality is higher among co-infected haemophilic than non-haemophilic candidates.

Trial registration: ClinicalTrials.gov NCT00473629.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Post-Transplant Outcomes in HIV-HCV Co-Infected Liver Transplant Recipients
The time to death (1A), graft loss (1B), and rejection (1C) in hemophilic (dashed line) and non-hemophilic transplant recipients (solid line).
Figure 1
Figure 1. Post-Transplant Outcomes in HIV-HCV Co-Infected Liver Transplant Recipients
The time to death (1A), graft loss (1B), and rejection (1C) in hemophilic (dashed line) and non-hemophilic transplant recipients (solid line).
Figure 1
Figure 1. Post-Transplant Outcomes in HIV-HCV Co-Infected Liver Transplant Recipients
The time to death (1A), graft loss (1B), and rejection (1C) in hemophilic (dashed line) and non-hemophilic transplant recipients (solid line).
Figure 2
Figure 2. Pre-Transplant Outcomes in HIV-HCV Co-Infected Hemophilic Liver Transplant Candidates
The time to death (2A), transplantation (2B), and MELD=25 (2C) in hemophilic (dashed line) and in non-hemophilic liver transplant candidates (solid line).
Figure 2
Figure 2. Pre-Transplant Outcomes in HIV-HCV Co-Infected Hemophilic Liver Transplant Candidates
The time to death (2A), transplantation (2B), and MELD=25 (2C) in hemophilic (dashed line) and in non-hemophilic liver transplant candidates (solid line).
Figure 2
Figure 2. Pre-Transplant Outcomes in HIV-HCV Co-Infected Hemophilic Liver Transplant Candidates
The time to death (2A), transplantation (2B), and MELD=25 (2C) in hemophilic (dashed line) and in non-hemophilic liver transplant candidates (solid line).
See this image and copyright information in PMC

References

    1. Ragni MV, Belle SH. Impact of human immunodeficiency virus (HIV) on progression to end-stage liver disease in individuals with hemophilia and hepatitis C. J Infect Dis. 2001;183:1112–15. - PubMed
    1. Roland ME, Stock PG. Solid organ transplantation in HIV-infected recipients. Semin Liver Dis. 2006;26:273–84. - PubMed
    1. Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, Andrade RJ, Gonzalez-Serrano M, Aguilar J, Aguilar-Guisado M, Navarro JM, Salmeron J, Caballero-Granado FJ, Francisco K. Garcia-Garcia JA, Grupo A. HIV co-infection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41:779–89. - PubMed
    1. Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim KA, Kim SS, Borges CB, Shao RX, Chung RT. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology. 2008;134:803–11. - PubMed
    1. DeVera ME, Dvorchik I, Tom K, Eghtesad B, Shakil O, Demetris A, Jain A, Fung JJ, Ragni MV. Survival of liver transplant patients co-infected with HIV and HCV: the impact of recurrent hepatitis C. Am J Transplantation. 2006;6:2983–93. - PubMed

Publication types

Associated data